11 citations
,
January 2000 in “The Journal of Steroid Biochemistry and Molecular Biology” This study found that LY320236 is a competitive inhibitor of type I and a non-competitive inhibitor of type II steroid 5alpha-reductase, indicating its potential as a dual inhibitor with differing modes of activity.
2 citations
,
September 2009 in “Hormone Molecular Biology and Clinical Investigation” This study found that low-dose finasteride treatment in men with premature androgenetic alopecia decreased levels of 5α-reduced steroids, which may be linked to increased depression symptoms.
12 citations
,
June 2007 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” This study developed a reliable and convenient cell-based model to screen for type II 5α-reductase inhibitors, identifying Curcumae longae and Mori ramulus extracts as potential candidates.
5 citations
,
January 2014 in “Molecular Simulation” This study discovered a potential new 5α-reductase type II inhibitor with higher predicted activity than finasteride, suggesting it as a promising candidate for treating benign prostatic hyperplasia.
In this study using a virtual screening approach, eriocitrin and silymarin were identified as potent flavonoid compounds that strongly and stably interacted with 5α-reductase type II, suggesting potential development as novel treatments for androgenic alopecia.